Insider Selling: GeneDx (NASDAQ:WGS) COO Sells 5,961 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) COO Bryan Dechairo sold 5,961 shares of the company’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $85.70, for a total value of $510,857.70. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Bryan Dechairo also recently made the following trade(s):

• On Monday, February 2nd, Bryan Dechairo sold 3,413 shares of GeneDx stock. The shares were sold at an average price of $99.53, for a total value of $339,695.89.

GeneDx Stock Performance

WGS traded up $0.21 on Friday, hitting $84.29. The company had a trading volume of 819,180 shares, compared to its average volume of 759,831. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of 936.56 and a beta of 2.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. The company’s fifty day moving average price is $127.79 and its 200 day moving average price is $124.57. GeneDx Holdings Corp. has a 1-year low of $55.17 and a 1-year high of $170.87.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Guggenheim reaffirmed a “buy” rating and set a $170.00 price objective (up from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. BTIG Research boosted their target price on shares of GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Canaccord Genuity Group raised their price target on GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Wells Fargo & Company set a $155.00 price objective on GeneDx and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Finally, Wall Street Zen raised GeneDx from a “hold” rating to a “buy” rating in a research report on Saturday, January 31st. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $138.13.

Institutional Trading of GeneDx

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp raised its position in shares of GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after buying an additional 186 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in GeneDx during the fourth quarter valued at about $35,000. Quarry LP raised its holdings in GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after acquiring an additional 209 shares in the last quarter. Gordian Capital Singapore Pte Ltd bought a new stake in shares of GeneDx in the 3rd quarter worth approximately $65,000. Finally, AlphaQuest LLC grew its holdings in shares of GeneDx by 351.5% during the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after purchasing an additional 594 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.